Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 109

Sort by

Sort Order Select

Journal Articles

A Hydrogel Based 3D Culture System for Hematopoietic Differentiation of Induced Pluripotent Stem Cells

Ishnoor Sidhu, Sonali Barwe, PhD MSc, E. Anders Kolb, MD, Kristi Lynn Kiick, PhD, Anilkumar Gopalakrishnapillai, PhD

Blood (2019) 134 (Supplement_1): 5010.

https://doi.org/10.1182/blood-2019-130949

Published: 2019

Journal Articles

Efficacy and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) Prophylaxis in Patients with Severe Hemophilia a and Comorbidities: A Post Hoc Analysis of PROTECT VIII Data

Wolfgang A. Miesbach, Giovanni Di Minno, Elena Santagostino, Dr. Klamroth, Inga Bayh, Amaryllis Soto, Cedric Hermans

Blood (2019) 134 (Supplement_1): 1117.

https://doi.org/10.1182/blood-2019-128486

Published: 2019

Journal Articles

Asparaginase-Associated Pancreatitis in ALL: Results from the NOPHO ALL2008 Treatment of Patients 1-45 Years

Blood (2019) 134 (Supplement_1): 3820.

https://doi.org/10.1182/blood-2019-122275

Published: 2019

Journal Articles

Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study

Jonathan M. Ducore, MD MPH, Shadan Lalezari, PhD, Elena Santagostino, MD PhD, Sanjay P Ahuja, MD, Monika Maas Enriquez, Claudia Tueckmantel, PhD, Mark Reding

Blood (2019) 134 (Supplement_1): 1129.

https://doi.org/10.1182/blood-2019-123947

Published: 2019

Journal Articles

Asparaginase Immune Complexes Detectable after Asparaginase-Induced Hypersensitivities Activate Basophils Via FcγRIII

Sanjay Rathod, PhD, Fred D Finkelman, MD, Christian Fernandez, PhD

Blood (2018) 132 (Supplement 1): 5210.

https://doi.org/10.1182/blood-2018-99-116704

Published: 2018

Journal Articles

Compassionate Use of Ropeginterferon-Alfa-2b/P1101 for Treatment of High Risk Polycythemia Vera and Essential Thrombocythemia Patients Previously Controlled on Pegylated Interferon-Alfa-2a/ Pegasys ®

Jeffrey A Gilreath, PharmD, Tsewang Tashi, MD, Soo Jin Kim, MS, Kimberly Hickman, BS, Josef T. Prchal, MD

Blood (2018) 132 (Supplement 1): 5459.

https://doi.org/10.1182/blood-2018-99-116852

Published: 2018

Journal Articles

Pegylated E. coli Asparaginase Desensitization: An Effective and Feasible Option for Pediatric Patients with Acute Lymphoblastic Leukemia Who Have Developed Hypersensitivity to Pegaspargase in the Absence of Asparaginase Erwinia Chrysanthemi availability

Anupam Verma, MD, Karin Chen, MD, Jacob Johnsen, PharmD, Phillip Barnette, MD

Blood (2018) 132 (Supplement 1): 5205.

https://doi.org/10.1182/blood-2018-99-119866

Published: 2018

Journal Articles

Pegaspargase Allergic Reactions Are Related to Anti-Pegaspargase Antibodies and to Intensity of Intrathecal Therapy

Blood (2018) 132 (Supplement 1): 2697.

https://doi.org/10.1182/blood-2018-99-110141

Published: 2018

Journal Articles

Characteristics of Bleed-Free Patients on Every-5-Day Dosing in the Protect VIII (BAY 94-9027) Study

Elena Santagostino, MD PhD, Bryce A. Kerlin, MD, Claude Negrier, Liu Tian, Dr, Jonathan M. Ducore, MD

Blood (2018) 132 (Supplement 1): 2486.

https://doi.org/10.1182/blood-2018-99-116031

Published: 2018

Journal Articles

Efficacy and Safety of Bay 94-9027 Is Sustained for 5 Years: Outcomes in 33 Patients in the Protect VIII Extension Study

Mark T. Reding, MD, Lone Hvitfeldt Poulsen, Liu Tian, Dr, Pal André Holme, PhD MD

Blood (2018) 132 (Supplement 1): 2492.

https://doi.org/10.1182/blood-2018-99-114659

Published: 2018

Journal Articles

Triple Degradation of BTK, IKZF1 and IKZF3 in B-Cell Malignancies

Sara Morrow, BA, Dennis Dobrovolsky, PhD, Eric Wang, PhD, Radosław P. Nowak, PhD, Katherine Donovan, PhD, Tyler Faust, PhD, Guang Yang, PhD, Zhengnian Li, PhD, Eric Fischer, Steven P Treon, MD PhD FRCP, David M Weinstock, MD, Nathanael S. Gray, PhD

Blood (2018) 132 (Supplement 1): 263.

https://doi.org/10.1182/blood-2018-99-116895

Published: 2018

Journal Articles

A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model

Dina Stroopinsky, PhD, Jessica Liegel, MD, Kathleen M. Mahoney, MD PhD, Jacalyn Rosenblatt, MD, Benjamin L. Ebert, MD PhD, Richard M. Stone, MD, Maryam Rahimian, MD, Myrna Nahas, MD, Shira Orr, PhD, Marzia Capelletti, PhD MMSc, Matthew Weinstock, MD, Salvia Jain, MD, Lina Bisharat, MA, Haider Ghiasuddin, BA, Adam Morin, BA, Donald Kufe, MD, Gordon J Freeman, PhD, David E. Avigan, MD

Blood (2018) 132 (Supplement 1): 1446.

https://doi.org/10.1182/blood-2018-99-120259

Published: 2018

Journal Articles

Extended Interval Prophylaxis with Bay 94-9027 for > 4 Years Leads to Median Spontaneous Annualized Bleeding Rates < 1 in the Protect VIII Extension

Mindy Simpson, MD, Sanjay Ahuja, Despina Tseneklidou-Stoeter, Dr, Shadan Lalezari, Dr

Blood (2018) 132 (Supplement 1): 1189.

https://doi.org/10.1182/blood-2018-99-114619

Published: 2018

Journal Articles

Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension

Mark T. Reding, MD, Shadan Lalezari, Dr, Ingrid Pabinger, MD, Monica Maas Enriquez, Dr, Jonathan M. Ducore, MD

Blood (2018) 132 (Supplement 1): 1206.

https://doi.org/10.1182/blood-2018-99-116272

Published: 2018

Journal Articles

Comparison of Immunogenicity between the Proposed Pegfilgrastim Biosimilar MYL-1401H and Reference Pegfilgrastim

C Waller, Gopinath M. Ranganna, Eduardo Pennella, Leonard A. Mattano, MD, Chien Chang Loa, Charles Donnelly, Mark Shiyao Liu, Heather Watson, Julien St-Jean, Sanjukta Chatterjee, Vivek Nayak, Nilanjan Sengupta, Mudgal A. Kothekar, Abhijit Barve

Blood (2017) 130 (Supplement 1): 3568.

https://doi.org/10.1182/blood.V130.Suppl_1.3568.3568

Published: 2017

Journal Articles

Polyethylene Glycol (PEG) Exposure in Parenteral Therapies Indicated for the Pediatric Population: History and Safety

Reinhard Stidl, PhD, Elizabeth Schwartz, PhD, Michael Denne, PharmD, Jimena Goldstine, PhD, Bill Kadish, MD, Katherine I. Korakas, PhD, Peter L. Turecek, PhD

Blood (2017) 130 (Supplement 1): 3666.

https://doi.org/10.1182/blood.V130.Suppl_1.3666.3666

Published: 2017

Journal Articles

A Point-of-Care Quartz Biosensor Chip for Detection of PF4/Heparin Complexes

Jennifer Minjia Chang, Gowthami Arepally, MD, Stefan Zauscher, PhD, Zehra Parlak, PhD

Blood (2017) 130 (Supplement 1): 2327.

https://doi.org/10.1182/blood.V130.Suppl_1.2327.2327

Published: 2017

Journal Articles

Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life in Previously Treated Pediatric Patients with Hemophilia Α: Efficacy of Prophylaxis and Treatment By Time (of Day/of Week) of Occurrence of Bleeding

Eric S. Mullins, MD, Christine M. Knoll, MD, Amy L. Dunn, MD, Werner Engl, PhD Cstat, Marlies Sharkhawy, MA, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 1409.

https://doi.org/10.1182/blood.V128.22.1409.1409

Published: 2016

Journal Articles

Development of a Triazolyldisulfide Compound That Increases the Affinity of Hemoglobin for Oxygen and Reduces Hypoxic Sickling of Sickle Cells

Akito Nakagawa, PhD, Ferrari Michele, MD, Chen Liu, PhD, Lorenzo Berra, MD, Elizabeth S. Klings, MD, Martin K. Safo, PhD, Donald B. Bloch, MD, Osheiza Abdulmalik, DVM, MS, Warren M. Zapol, MD

Blood (2016) 128 (22): 3642.

https://doi.org/10.1182/blood.V128.22.3642.3642

Published: 2016

Journal Articles

Target Joint Bleeding in Pediatric Patients with Hemophilia Α Receiving Twice Weekly Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Amy L. Dunn, MD, Alexis A. Thompson, MD MPH, Werner Engl, PhD Cstat, Marlies Sharkhawy, MA, Brigitt E. Abbuehl, MD

Blood (2016) 128 (22): 3778.

https://doi.org/10.1182/blood.V128.22.3778.3778

Published: 2016

NARROW

A Hydrogel Based 3D Culture System for Hematopoietic Differentiation of Induced Pluripotent Stem Cells

Efficacy and Safety of BAY 94-9027 (Damoctocog Alfa Pegol) Prophylaxis in Patients with Severe Hemophilia a and Comorbidities: A Post Hoc Analysis of PROTECT VIII Data

Asparaginase-Associated Pancreatitis in ALL: Results from the NOPHO ALL2008 Treatment of Patients 1-45 Years

Improvement in Quality of Life Outcomes and Bleeding Rates among Patients Switching from On-demand FVIII to Prophylactic BAY 94-9027 in the PROTECT VIII Study

Asparaginase Immune Complexes Detectable after Asparaginase-Induced Hypersensitivities Activate Basophils Via FcγRIII

Compassionate Use of Ropeginterferon-Alfa-2b/P1101 for Treatment of High Risk Polycythemia Vera and Essential Thrombocythemia Patients Previously Controlled on Pegylated Interferon-Alfa-2a/ Pegasys ®

Pegylated E. coli Asparaginase Desensitization: An Effective and Feasible Option for Pediatric Patients with Acute Lymphoblastic Leukemia Who Have Developed Hypersensitivity to Pegaspargase in the Absence of Asparaginase Erwinia Chrysanthemi availability

Pegaspargase Allergic Reactions Are Related to Anti-Pegaspargase Antibodies and to Intensity of Intrathecal Therapy

Characteristics of Bleed-Free Patients on Every-5-Day Dosing in the Protect VIII (BAY 94-9027) Study

Efficacy and Safety of Bay 94-9027 Is Sustained for 5 Years: Outcomes in 33 Patients in the Protect VIII Extension Study

Triple Degradation of BTK, IKZF1 and IKZF3 in B-Cell Malignancies

A Novel Monoclonal Antibody Combination Plus DC/AML Fusion Vaccine Eradicates AML in an Immunocompetent Murine Model

Extended Interval Prophylaxis with Bay 94-9027 for > 4 Years Leads to Median Spontaneous Annualized Bleeding Rates < 1 in the Protect VIII Extension

Decrease in Overall and Joint Bleeding Rates with Extended-Interval Dosing: > 4 Years of Bay 94-9027 Prophylaxis in the Protect VIII Extension

Comparison of Immunogenicity between the Proposed Pegfilgrastim Biosimilar MYL-1401H and Reference Pegfilgrastim

Polyethylene Glycol (PEG) Exposure in Parenteral Therapies Indicated for the Pediatric Population: History and Safety

A Point-of-Care Quartz Biosensor Chip for Detection of PF4/Heparin Complexes

Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life in Previously Treated Pediatric Patients with Hemophilia Α: Efficacy of Prophylaxis and Treatment By Time (of Day/of Week) of Occurrence of Bleeding

Development of a Triazolyldisulfide Compound That Increases the Affinity of Hemoglobin for Oxygen and Reduces Hypoxic Sickling of Sickle Cells

Target Joint Bleeding in Pediatric Patients with Hemophilia Α Receiving Twice Weekly Prophylaxis with a Pegylated Full-Length Recombinant Factor VIII with Extended Half-Life

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only